Abstract:Biologics are frequently switched in psoriatic patients who do not respond adequately or experience adverse events under treatment. 1,2 While several studies have demonstrated efficacy and safety when switching between interleukin (IL)-17 inhibitors, 3-5 there is no such published data regarding IL-23 antagonists. We report a patient with psoriasis who was successfully treated with risankizumab after secondary nonresponse to ustekinumab and primary nonresponse to guselkumab and tildrakizumab.
scite is a Brooklyn-based startup that helps researchers better discover and evaluate scientific articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by researchers from dozens of countries and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.